BoXer releases this 'payload' locally at the site of bone lesions, offering a dual therapeutic benefit—bone regeneration and localized myeloma control," adds Dr. Anja Seckinger of TORC.

leading to debilitating bone lesions in 80% of patients. These lesions cause severe pain and fractures that often fail to heal, and within, a vicious cycle takes place that supports tumor survival ...

The team tackled a critical challenge in treating multiple myeloma -- a blood cancer where malignant plasma cells accumulate in bone marrow, leading to debilitating bone lesions in 80% of patients.

leading to debilitating bone lesions in 80% of patients. These lesions cause severe pain and fractures that often fail to heal, and within them, a vicious cycle takes place that supports tumor ...

In a clinical abstract session on imaging aspects of ... OP0222 Sacroiliac bone marrow oedema on postpartum MRI does not ...